SUVmax and SUVmean of Organs, Primary Tumors, and Metastases in Treated and Untreated Patients
| Parameter | Octreotide | No octreotide | P |
| Most intense metastases per patient | |||
| SUVmax | 32.5 ± 16.6 (10.8–70.1) | 33.0 ± 23.0 (6.3–117.1) | 0.73 |
| SUVmean | 11.2 ± 6.8 (3.7–25.6) | 10.6 ± 5.1 (3.6–21.8) | 0.83 |
| Primary tumor | |||
| SUVmax | 28.6 ± 6.8 (23.8–33.4) | 32.9 ± 31.5 (6.3–117.1) | 0.69 |
| SUVmean | 19.8 ± 6.7 (15.1–24.5) | 21.3 ± 19.5 (4.1–72.7) | 0.55 |
| Liver metastases | |||
| SUVmax | 27.2 ± 14.8 (8.1–66.4) | 25.7 ± 10.7 (9.8–56.8) | 0.92 |
| SUVmean | 18.5 ± 10.7 (5.2–46.3) | 16.9 ± 7.5 (6.9–39.9) | 0.83 |
| Lymph node metastases | |||
| SUVmax | 41.4 ± 19.5 (5.6–68.8) | 25.0 ± 6.3 (18.1–33.0) | 0.20 |
| SUVmean | 27.1 ± 13.1 (3.6–45.7) | 16.4 ± 4.8 (11.2–22.0) | 0.17 |
| Osseous metastases | |||
| SUVmax | 39.5 ± 22.0 (11.5–70.1) | 15.4 ± 7.8 (10.2–27.0) | 0.49 |
| SUVmean | 26.9 ± 15.7 (6.6–48.6) | 10.2 ± 5.1 (6.7–17.8) | 0.38 |
| Lung metastases | |||
| SUVmax | None | 21.4 ± 11.0 (13.7–29.2) | NA |
| SUVmean | None | 14.0 ± 7.1 (9.0–19.0) | NA |
| Liver | |||
| SUVmax | 7.1 ± 2.1 (3.5–11.9) | 9.3 ± 2.9 (3.7–19.2) | <0.001 |
| SUVmean | 4.9 ± 1.4 (2.8–7.4) | 6.6 ± 1.9 (2.8–12.8) | <0.001 |
| Spleen | |||
| SUVmax | 18.4 ± 6.4 (9.5–31.8) | 24.9 ± 6.7 (10.4–43.8) | <0.001 |
| SUVmean | 12.8 ± 4.4 (6.4–23.5) | 18.2 ± 5.0 (7.2–32.8) | <0.001 |
| Adrenal gland | |||
| SUVmax | 18.3 ± 5.7 (9.4–28.0) | 20.0 ± 5.6 (10.1–41.2) | 0.70 |
| SUVmean | 11.7 ± 3.7 (6.0–17.7) | 14.9 ± 16.4 (7.2–18.5) | 0.76 |
| Pituitary gland | |||
| SUVmax | 3.9 ± 4.8 (0.4–19.3) | 2.0 ± 0.8 (0.5–3.5) | 0.12 |
| SUVmean | 2.6 ± 3.2 (0.3–13.0) | 1.3 ± 0.5 (0.3–2.4) | 0.08 |
| Kidney | |||
| SUVmax | 14.5 ± 6.0 (5.9–31.0) | 15.8 ± 4.6 (8.3–35.0) | 0.24 |
| SUVmean | 9.5 ± 3.3 (4.1–17.3) | 10.4 ± 2.8 (5.4–22.5) | 0.32 |
NA = not applicable.
Data are mean ± SD, with range in parentheses.